Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.76 USD | +1.34% | -1.73% | +18.91% |
31/05 | Qiagen, Myriad Genetics Team Up to Develop Homologous Recombination Deficiency Test | MT |
31/05 | Qiagen, Myriad Genetics Partner to Create Easily Distributable Cancer Tumor Test | MT |
Business Summary
Number of employees: 2,700
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Hereditary Cancers
43.5
%
| 306 | 45.0 % | 328 | 43.5 % | +7.30% |
Prenatal
20.1
%
| 116 | 17.2 % | 151 | 20.1 % | +29.98% |
Pharmacogenomics
18.4
%
| 128 | 18.8 % | 139 | 18.4 % | +8.54% |
Tumor Profiling
18.0
%
| 129 | 19.0 % | 136 | 18.0 % | +5.44% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
89.2
%
| 592 | 87.2 % | 672 | 89.2 % | +13.56% |
Rest of World
10.8
%
| 87 | 12.8 % | 82 | 10.8 % | -6.21% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Paul Diaz
CEO | Chief Executive Officer | 61 | 13/20/13 |
Scott Leffler
DFI | Director of Finance/CFO | 49 | 29/01 |
Dale Muzzey
CTO | Chief Tech/Sci/R&D Officer | 44 | 01/14/01 |
Thomas P. Slavin
CTO | Chief Tech/Sci/R&D Officer | - | 01/20/01 |
Kevin Haas
CTO | Chief Tech/Sci/R&D Officer | 38 | 01/18/01 |
Samraat Raha
COO | Chief Operating Officer | 52 | 11/12 |
Glenn Farrell
IRO | Public Communications Contact | - | 19/22/19 |
Matthew Scalo
IRC | Investor Relations Contact | - | 01/22/01 |
John Oberg
PRN | Corporate Officer/Principal | - | 03/23/03 |
Natalie Munk
AUD | Comptroller/Controller/Auditor | 43 | 01/20/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
S. Phanstiel
CHM | Chairman | 65 | 16/09/16 |
Paul Bisaro
BRD | Director/Board Member | 63 | 31/22/31 |
Dan Spiegelman
BRD | Director/Board Member | 65 | 27/20/27 |
Paul Diaz
CEO | Chief Executive Officer | 61 | 13/20/13 |
Lee Newcomer
BRD | Director/Board Member | 71 | 25/19/25 |
Colleen Reitan
BRD | Director/Board Member | 64 | 25/19/25 |
Heiner Dreismann
BRD | Director/Board Member | 69 | 10/10/10 |
Director/Board Member | 50 | 21/20/21 | |
Rashmi Kumar
BRD | Director/Board Member | 53 | 10/20/10 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 90,507,981 | 88,619,254 ( 97.91 %) | 0 | 97.91 % |
Company contact information
Sector
Sales per Business
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.91% | 2.06B | |
-3.17% | 8.22B | |
+6.11% | 5.72B | |
+31.98% | 5.67B | |
-10.03% | 4.11B | |
-59.94% | 2.68B | |
+11.23% | 2.68B | |
-5.14% | 2.37B | |
-7.56% | 1.8B | |
+3.07% | 1.6B |
- Stock Market
- Equities
- MYGN Stock
- Company Myriad Genetics, Inc.